In spite of the recent introduction of two new drugs (delamanid and bedaquiline) and a few
repurposed compounds to treat multidrug-resistant and extensively drug-resistant …

In order to improve the adherence and treatment outcomes of multidrug-resistant (MDR)
tuberculosis (TB) patients, the World Health Organization (WHO) has recently recommended …

SETTING: Individualised regimens based on drug susceptibility test results, generally used
to treat multidrug-resistant tuberculosis (MDR-TB), require often unavailable expertise and …

The emergence of drug-resistant tuberculosis (TB) compromises global tuberculosis control.
The incidence of multidrug-resistant strains (MDR) defined as resistant to the two main …

In Pakistan, the treatment of multidrug-resistant tuberculosis (MDR-TB) with a shorter
treatment regimen (STR), that is, 4–6 months of amikacin, moxifloxacin (Mfx), ethionamide …

Background India has the world's highest tuberculosis burden, and Mumbai is particularly
affected by multidrug resistant tuberculosis (MDR-TB). WHO recommends short, intensive …

Multidrug-resistant tuberculosis (MDR-TB) is a major public health challenge, with an
estimated 480 000 new cases emerging globally each year [1]. Treatment success rates …

National tuberculosis programmes (NTPs) should aim for achieving a very high proportion of
cure of all tuberculosis (TB) cases. Ineffective chemotherapy of TB that keeps a substantial …

Background In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of
multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current …

SETTING: Tuberculosis (TB) program, Damien Foundation Projects, Bangladesh.
OBJECTIVE: To summarize the outcome and its determinants of the first treatment for …